Literature DB >> 16818185

Bladder cancer: toward state of the art multidisciplinary molecular medicine.

Hani H Rashid1, Kenneth S Koeneman.   

Abstract

Recent advances in bladder cancer research, and clinical diagnosis and therapy are explored. Major advances in biologic understanding are applied toward better early diagnosis and staging. Using molecular medicine to help informed clinical trial design and implementation will lead to more effective therapeutic intervention in transitional cell carcinoma. Interdisciplinary care and multimodal approach will allow better outcomes, stage for stage and grade for grade. The challenge is for clinician-scientists to integrate basic and translational advances efficiently and rapidly into the clinic, recognizing the value of a multifaceted paradigm.

Entities:  

Mesh:

Year:  2006        PMID: 16818185     DOI: 10.1016/j.urolonc.2005.11.029

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  1 in total

1.  Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Fabrizio Di Maida; Cristina Scalici Gesolfo; Riccardo Tellini; Andrea Mari; Chiara Sanfilippo; Luca Lambertini; Antonio Andrea Grosso; Marco Carini; Andrea Minervini; Vincenzo Serretta
Journal:  Ther Adv Urol       Date:  2021-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.